Adiponectin is increased in cardiac cachexia irrespective of body mass index

Araújo, José Paulo; Lourenço, Patrícia; Rocha-Gonçalves, Francisco; Ferreira, António; Bettencourt, Paulo

doi:10.1093/eurjhf/hfp046

Cited by 45 publications

(17 citation statements)

References 29 publications

(49 reference statements)

Supporting

Mentioning

Contrasting

Order By: Relevance

“…For instance, adiponectin may activate NF- κ B and AP-1, resulting in expression of proinflammatory genes and enhancement of angiotensin II-induced proliferation in cardiac fibroblasts, which may in turn play a role in heart failure progression 31, 32) . Moreover, adiponectin can increase energy expenditure and decrease body weight, which may participate in the development of cardiac cachexia 33, 34) . Therefore, the increase in plasma adiponectin in chronic heart failure can also represent shortterm beneficial adaptive responses on acute injury, which may eventually turn into harmful maladaptive signals on prolonged and chronic activation, like the sustained sympathetic hyperactivity in the advanced heart failure 35) .…”

Section: Discussionmentioning

confidence: 99%

Endothelin-1-Induced Cell Hypertrophy in Cardiomyocytes is Improved by Fenofibrate: Possible Roles of Adiponectin

Jen

Yin

Chen

et al. 2017

JAT

View full text Add to dashboard Cite

Aim: Previous studies demonstrated that endothelin-1 (ET-1) can significantly increase the cell size and stimulate adiponectin expression in cultured human cardiomyocytes (HCM). The aim of the present study was to investigate the effects of fenofibrate, a peroxisome proliferator-activated receptor-α (PPARα) activator, on cell hypertrophy and adiponectin expression in vitro and in a rat model of daunorubicin-induced cardiomyopathy.Methods: The cultured human cardiomyocytes (HCM) were stimulated with or without ET-1. The cell size and the protein expressions of PPARα and adiponectin were tested by confocal Immunofluorescence study and Western blot, respectively. To study the effects of PPARα activation on ET-1-induced cell hypertrophy and adiponectin protein synthesis, HCM were pretreated with fenofibrate or small interfering RNA (siRNA) of PPARα. Echocardiographic parameters were measured and immunohistochemistry study of myocardial adiponectin expression was conducted in the in vivo study.Results: ET-1 significantly increased the cell size, dose-dependently suppressed the expression of PPARα, and enhanced the expression of adiponectin; whereas, such an increase of cell size and enhancement of adiponectin expression were inhibited by the pre-treatment with fenofibrate. Addition of siRNA of PPARα abolished the effects of fenofibrate. Moreover, we found that fenofibrate treatment can significantly improve the left ventricular function and reverse the myocardial expression of adiponectin.Conclusions: Our study shows that fenofibrate may protect against ET-1-induced cardiomyocyte hypertrophy and enhanced adiponectin expression through modulation of PPARα expression in vitro and limitation of daunorubicin cardiotoxicity in vivo, suggesting a novel mechanistic insight into the role of PPARα and adiponectin in cardiac hypertrophy and heart failure.

show abstract

Section: Discussionmentioning

confidence: 99%

Endothelin-1-Induced Cell Hypertrophy in Cardiomyocytes is Improved by Fenofibrate: Possible Roles of Adiponectin

Jen

Yin

Chen

et al. 2017

JAT

View full text Add to dashboard Cite

show abstract

“…[49, 50] In contrast, cachexia has been associated with increases in adiponectin, even when controlling for BMI. [51] In the elderly, higher adiponectin levels also correlate with mortality, are associated with frailty, and can be modified by exercise. [52, 53] High adiponectin levels have also been shown to be associated with poor outcomes in patients in the ICU, independent of BMI or markers of inflammation.…”

Section: Discussionmentioning

confidence: 99%

Serum Adiponectin Is Associated with Worsened Overall Survival in a Prospective Cohort of Hepatocellular Carcinoma Patients

et al. 2014

View full text Add to dashboard Cite

Background: Hepatocellular carcinoma (HCC) is the third leading cause of cancer deaths worldwide. The rise in metabolic syndrome has contributed to this trend. Adipokines, such as adiponectin, are associated with prognosis in several cancers, but have not been well studied in HCC. Methods: We prospectively enrolled 140 patients with newly diagnosed or recurrent HCC with Child-Pugh (CP) class A or B cirrhosis. We examined associations between serum adipokines, clinicopathological features of HCC, and time to death. We also examined a subset of tumors with available pathology for tissue adiponectin receptor (AR) expression by immunohistochemistry. Results: The median age of subjects was 62 years; 79% were men, 59% had underlying hepatitis C, and 36% were diabetic. Adiponectin remained a significant predictor of time to death (hazard ratio 1.90; 95% confidence interval 1.05-3.45; p = 0.03) in a multivariable adjusted model that included age, alcohol history, CP class, stage, and serum E-fetoprotein level. Cytoplasmic AR expression (AR1 and AR2) in tumors trended higher in those with higher serum adiponectin levels and in those with diabetes mellitus, but the association was not statistically significant. Conclusions: In this hypothesis-generating study, we found the serum adiponectin level to be an independent predictor of overall survival in a diverse cohort of HCC patients. Impact: Understanding how adipokines affect the HCC outcome may help develop novel treatment and prevention strategies. i 2014 S. Karger AG, Basel

show abstract

“…Inflammation is a key factor for PEW in patients with end-stage kidney disease who are under dialysis [26]. Moreover, several clinical studies have demonstrated cross-talk between cardiac cachexia, BNP, and adiponectin in chronic heart failure patients [27,28]; this suggests that NT-proBNP and inflammatory biomarkers, and adiponectin interact with nutritional status in those patients. In the present study, NT-proBNP was correlated with hsCRP and IL-6 levels, and hsCRP predicted change in and loss of LBM.…”

Section: Discussionmentioning

confidence: 99%

N-Terminal Pro-B-Type Natriuretic Peptide as a Biomarker for Loss of Muscle Mass in Prevalent Hemodialysis Patients

Ikeda

Honda

Takahashi³

et al. 2016

PLoS ONE

View full text Add to dashboard Cite

Protein-energy wasting (PEW) is common in hemodialysis (HD) patients. A recent study demonstrated that a high level of N-terminal pro-B-type natriuretic peptide (NT-proBNP) may be associated with PEW in those patients. This prospective study aimed to assess the association of NT-proBNP with body composition and muscle loss. A cohort of prevalent HD patients (n = 238) was examined. Blood samples were obtained at baseline to measure high-sensitive C-reactive protein (hsCRP), interleukin-6 (IL-6), adiponectin and NT-proBNP. Nutritional status and changes in muscle mass were assessed by subjective global assessment, percentage creatinine generation rate (%CGR), creatinine index (CI) and lean body mass (LBM) estimated by dual-energy X-ray absorptiometry (DXA). The %CGR and CI were calculated five times for one year, and DXA was performed at baseline and one year later. Cardiac function was estimated by ultrasonography at baseline. NT-proBNP was significantly higher in HD patients with PEW. High NT-proBNP was associated with cardiac dysfunction, increased levels of hsCRP and IL-6, and serially decreased levels of the indexes for muscle mass. Multiple regression analysis adjusted with confounders showed that NT-proBNP was an independent predictor for decrease in LBM and serial lower levels of %CGR and CI. In conclusion, the present study demonstrated a novel association between NT-proBNP and muscle loss. NT-proBNP may be an independent biomarker for malnutrition in HD patients, especially in patients with muscles loss, regardless of chronic inflammation, cardiac dysfunction, or overhydration.

show abstract

Adiponectin is increased in cardiac cachexia irrespective of body mass index

Cited by 45 publications

References 29 publications

Endothelin-1-Induced Cell Hypertrophy in Cardiomyocytes is Improved by Fenofibrate: Possible Roles of Adiponectin

Endothelin-1-Induced Cell Hypertrophy in Cardiomyocytes is Improved by Fenofibrate: Possible Roles of Adiponectin

Serum Adiponectin Is Associated with Worsened Overall Survival in a Prospective Cohort of Hepatocellular Carcinoma Patients

N-Terminal Pro-B-Type Natriuretic Peptide as a Biomarker for Loss of Muscle Mass in Prevalent Hemodialysis Patients

Contact Info

Product

Resources

About